BGI Global Economic Services
Sentis - Molecular Diagnostics

BGI SENTISTM Cancer+Discovery

The Power Of Knowing

CAP Accredited

BGI’s Cancer + Discovery Panel (BGI C + D Panel) provides one of the most comprehensive and accurate Next Generation Sequencing (NGS) solution for the identification of

hospital Clinically actionable mutations (somatic & genetic variants)

hospital TMB and MSI status

hospital Discovery of novel variants (with important functions in cancer)

hospital Drug sensitivity /toxicity

Whole Exon Coverage

Major genetic alterations

FDA & NCCN guideline drug recommendation

Why choose us?




For more information on BGI’s Cancer+ Discovery Test :